Literature DB >> 16112862

Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency.

S Bogen1, A K Saksena, A Arasappan, H Gu, F G Njoroge, V Girijavallabhan, J Pichardo, N Butkiewicz, A Prongay, V Madison.   

Abstract

Modification of the P(2) and P(1) side chains of earlier P(3)-capped alpha-ketoamide inhibitor of HCV NS3 serine protease 1 resulted in the discovery of compound 24 with about 10-fold improvement in potency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112862     DOI: 10.1016/j.bmcl.2005.07.009

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Target assessment for antiparasitic drug discovery.

Authors:  Julie A Frearson; Paul G Wyatt; Ian H Gilbert; Alan H Fairlamb
Journal:  Trends Parasitol       Date:  2007-10-24

2.  Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study.

Authors:  Ahmed A Ezat; Abdo A Elfiky; Wael M Elshemey; Noha A Saleh
Journal:  Virusdisease       Date:  2019-03-21

Review 3.  The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease.

Authors:  Anita Y M Howe; Srikanth Venkatraman
Journal:  J Clin Transl Hepatol       Date:  2013-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.